Initial use of the new GORE® septal occluder in patent foramen ovale closure: Implantation and preliminary results

被引:12
作者
MacDonald, Simon T. [1 ]
Daniels, Matthew J. [1 ]
Ormerod, Oliver J. [1 ]
机构
[1] John Radcliffe Hosp, Dept Cardiol, Oxford OX3 9DU, England
基金
英国惠康基金;
关键词
patent foramen ovale; septal occluder; AMPLATZER; DEVICES; DEFECT; RECOMMENDATIONS; EFFICACY; EROSION;
D O I
10.1002/ccd.24405
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background A number of devices are available for percutaneous closure of a clinically significant patent foramen ovale (PFO). The new GORE (R) septal occluder (GSO) is a nonself-centering device consisting of an expanded polytetrafluoroethylene tube supported by a frame of nitinol wire conforming into a double disk. This study reports the first clinical GSO implantation experience. Methods GSO implantation in 20 consecutive patients is reported. Inclusion criteria were all patients referred with a significant PFO implicated in paradoxical embolism or transient right to left shunting causing desaturation. Procedures were performed under local anaesthesia and intracardiac echocardiography (ICE) in addition to fluoroscopy. Procedural data, acute and early closure rates were examined. Results All patients underwent successful day-case device implantation. Eleven patients had previous stroke, five had transient ischemic attacks, two had a history suspicious of PFO-related desaturation, and two had a history suspicious of PFO-related peripheral thromboembolism. Acute closure rates on IVC injection bubble testing were 100% at implant and 100% (14/14) at 1 month. Average PFO balloon size was 8.0 +/- 3.6(range 2.016.7) mm, mean fluoroscopic implantation time 3.0 +/- 1.7(range 0.76.3) min, radiation dose 283 +/- 340 (range 61,431) Gym2, and total procedural time 34.8 +/- 8.0 (range 2253) min. 5 x 20 mm2, 7 x 25 m2, 8 x 30 mm2 GSO devices were implanted, aiming for device size at least twice balloon PFO size. Cases included aneurysmal septums with up to 30 mm deviation and tunnels up to 12 mm long. Removal and repositioning of two devices was performed on two occasions after uncertainty about device locking. At 1 month follow-up, two patients had brief self-terminating episodes of suspected atrial fibrillation, all had normal resting ECGs. No thromboembolic/neurological events were reported. Conclusions The GSO can be implanted under local anaesthesia and ICE with low procedural and fluoroscopy times with high procedural success as a day case. No residual shunts were seen. This initial experience suggests that it is a safe and effective device for PFO closure. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:660 / 665
页数:6
相关论文
共 17 条
[1]   Erosion of amplatzer septal occluder device after closure of secundum atrial septal defects: Review of registry of complications and recommendations to minimize future risk [J].
Amin, Z ;
Hijazi, ZM ;
Bass, JL ;
Cheatham, JP ;
Hellenbrand, WE ;
Kleinman, CS .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2004, 63 (04) :496-502
[2]   Late cardiac perforation after transcatheter closure of patent foramen ovale [J].
Cecconi, M ;
Quarti, A ;
Bianchini, F ;
Bucari, S ;
Costantini, C ;
Giovagnoni, A ;
Perna, GP .
ANNALS OF THORACIC SURGERY, 2006, 81 (06) :E29-E30
[3]   Incomplete Endothelialization and Late Dislocation After Implantation of an Amplatzer Septal Occluder Device [J].
Chen, Feng ;
Zhao, Xianxian ;
Zheng, Xing ;
Chen, Shaoping ;
Xu, Rongliang ;
Qin, Yongwen .
CIRCULATION, 2011, 124 (06) :E188-E189
[4]  
Delaney Jeffrey W, 2006, Congenit Heart Dis, V1, P202, DOI 10.1111/j.1747-0803.2006.00036.x
[5]   Erosion by the Amplatzer Septal Occluder: Experienced Operator Opinions at Odds With Manufacturer Recommendations? [J].
El-Said, Howaida G. ;
Moore, John W. .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2009, 73 (07) :925-930
[6]   Stroke due to late device thrombosis following successful percutaneous patent foramen ovale closure [J].
Korabathina, Ravikiran ;
Thaler, David E. ;
Kimmelstiel, Carey .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2012, 80 (03) :498-502
[7]   Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients [J].
Krumsdorf, U ;
Ostermayer, S ;
Billinger, K ;
Trepels, T ;
Zadan, E ;
Horvath, K ;
Sievert, H .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (02) :302-309
[8]  
MacDonald ST, 2010, EXPERT REV CARDIOVAS, V8, P1741, DOI [10.1586/erc.10.165, 10.1586/ERC.10.165]
[9]   A Biodegradable Device (BioSTAR™) for Atrial Septal Defect Closure in Children [J].
Morgan, Gareth ;
Lee, Kyong-Jin ;
Chaturvedi, Rajiv ;
Benson, Lee .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2010, 76 (02) :241-245
[10]   Single Centre Experience with GORE-HELEX Septal Occluder for Closure of PFO [J].
Ponnuthurai, Francis A. ;
van Gaal, William J. ;
Burchell, Amy ;
Mitchell, Andrew ;
Wilson, Neil ;
Ormerod, Oliver .
HEART LUNG AND CIRCULATION, 2009, 18 (02) :140-142